Our Companies

AXIM Biotechnologies

Our Accomplishments

› Owns the patent for chewing gum as a delivery method for cannabinoids. Read more.

› In clinical trials for MedChewRX for pain and spasticity in multiple sclerosis patients. Read more.

› Proof of concept trials underway for their patent pending AX-1602 proprietary ointment for the treatment of eczema and psoriasis. Read more.

› Proud donor to veterans through the “Adopt-a-Soldier Platoon”. Read more.

Latest AXIM Biotechnologies News

Medical Marijuana, Inc. Family of Companies Surpass Last Year’s Revenue with 5 Months Left in 2018

Medical Marijuana, Inc. rides momentum from first half of the year to pass last year’s revenue numbers with just five months left in 2018 Medical Marijuana, Inc. started off the year on the right foot in January – hitting record revenue numbers for the month. It is a feat Medical Marijuana, Inc. would repeat in […]

Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules

SAN DIEGO, Feb. 28, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced that its major investment company AXIM® Biotechnologies (OTC:AXIM) (“AXIM”) has successfully executed their first-ever proprietary current good manufacturing practices (“cGMP”) methodology in the extraction and microencapsulation of cannabinoid molecules for a variety of pharmaceutical delivery formats from […]

MMJ Reporter Trumpets Dutch Scientists’ Landmark Trial Tests of CanChew® Plus from AXIM® Biotechnologies

A marijuana-focused news outlet recently spotlighted MJNA investment company AXIM® Biotechnologies and its upcoming trial of its cannabinoid-based gum for IBS.

AXIM Biotechnologies Takes First Steps Towards Clinical Trials for CBD-Based Treatment of Drug-Related Psychosis

Since securing additional funding last fall, AXIM® Biotechnologies has expanded its ongoing new drug research to include treatments for opioid addiction, irritable bowel syndrome, multiple sclerosis, psoriasis and eczema, and restless leg syndrome. AXIM® Biotechnologies is now taking the necessary steps to begin clinical trials for the treatment of a new condition – psychosis. The [...]